Wegovy® (semaglutide) 2.4 mg is a once-weekly injectable prescription treatment intended to be used alongside a reduced-calorie diet and increased physical activity. It is approved to help lower the risk of major cardiovascular events—such as heart attack, stroke, or cardiovascular-related death—in adults with established heart disease who also have obesity or are overweight. Additionally, Wegovy® can support weight loss and long-term weight management in adults and in adolescents 12 years and older with obesity, as well as in adults who are overweight and have weight-related health concerns. Its active ingredient, semaglutide, is FDA-approved for chronic weight management. Because Wegovy® contains semaglutide, it should not be used with other medications that include semaglutide or with other GLP-1 receptor agonists. A prescription is required. For complete details and important safety information, visit https://www.wegovy.com.